Lessons from the Unrestricted Use of Drug-Eluting Stents: Insights from the RESEARCH and T-SEARCH Registry.
Drug-eluting stents have raised the current interventional practice to a new and higher level. With the commercializa-tion of sirolimus-and paclitaxel-eluting stents in 2002 and 2003 respectively, the range of applications for coronarystenting expanded. The growing confidence in these drug-eluting devices is based on their capability to reducerestenosis when compared to bare metal stents. We performed two prospective cohort studies, namely the RESEARCH and T-SEARCH registries, to evaluate the safety and efficacy of both the types of drug-eluting stents in a "real world," unselected patient population, in which they were used in almost every type of coronary lesion. In specifichigh-risk subsets, the use of sirolimus eluting stent was associated with a better outcome in terms of major adversecardiac events compared to bare metal stents. The T-SEARCH registry did not show a difference in clinical outcomebetween both devices up to two years. It is still a topic of debate in some countries whether this new technology shouldbecome a standard treatment because of the associated higher costs.
Daemen
Joost
J
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Serruys
Patrick W
PW